Verastem Inc ((VSTM)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Verastem Inc. is currently recruiting for a Phase 3 study titled A Phase 3, Randomized, Open-Label Study of Combination Therapy With Avutometinib Plus Defactinib Versus Investigator’s Choice of Treatment in Patients With Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (RAMP 301). The study aims to assess the safety and efficacy of the combination of avutometinib and defactinib compared to standard treatments for patients with recurrent LGSOC who have previously undergone platinum-based therapy.
The study tests the combination of two kinase inhibitors, avutometinib and defactinib, which are designed to block cancer cell growth. This investigational treatment is compared against standard care options, including Pegylated liposomal doxorubicin, Paclitaxel, Anastrozole, and Letrozole.
This international, randomized, open-label study employs a crossover design with no masking, focusing on treatment as its primary purpose. Participants are randomly assigned to receive either the investigational combination or one of the standard treatments, with an option to switch to the investigational drugs if disease progression occurs.
The study officially began on March 18, 2024, with the last update submitted on June 27, 2025. These dates are crucial as they mark the study’s progression and the latest data available for analysis.
The outcome of this study could significantly influence Verastem’s stock performance, as positive results may enhance investor confidence and market positioning. The study’s progress is particularly relevant in the competitive landscape of ovarian cancer treatments, where advancements can shift market dynamics.
The study is ongoing, and further details are available on the ClinicalTrials portal.